4-{[butyl(methyl)amino]sulfonyl}-N-(5-thien-2-yl-1,3,4-oxadiazol-2-yl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{[butyl(methyl)amino]sulfonyl}-N-(5-thien-2-yl-1,3,4-oxadiazol-2-yl)benzamide
• 英文别名: 4-[butyl(methyl)sulfamoyl]-N-(5-thiophen-2-yl-1,3,4-oxadiazol-2-yl)benzamide
• 化学式: C₁₈H₂₀N₄O₄S₂
• 分子量: 420.5
• InChiKey: FDYCCWQHNPUFGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  142
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• COMPOUNDS TARGETING THE VEGF AND/OR HIF PATHWAY SUCH AS SORAFENIB OR VATALANIB FOR USE IN THE TREATMENT OF OTITIS MEDIA
  申请人：Cheeseman Michael T.

  公开号：US20130078260A1

  公开（公告）日：2013-03-28

  The present invention provides a compound which targets the VEGF and/or HIF pathways for use in the treatment and/or prevention of otitis media in a subject. The invention also provides a pharmaceutical composition comprising such a compound and a method for treating and/or preventing otitis media in a subject which comprises the step of administering such a compound or pharmaceutical composition to the subject.